Search

We compared the value of gadolinium-enhanced first-pass MRI perfusion studies and HMPAO-SPECT for the assessment of regional cerebral blood flow in a prospective study of 23 intracranial tumour patients. In five tumours with homogeneous hypoperfusion and eight tumours with homogeneous hyperperfusion, tumour blood flow patterns in MRI and HMPAO-SPECT were similar. By contrast, in ten patients with inhomogeneous tumour blood flow pattern only MRI was able to differentiate between tumour areas with no or low flow, tumour tissue with high flow, and perifocal oedema with reduced flow. In HMPAO-SPECT, these inhomogeneous tumours were represented as areas of homogeneously reduced tracer retention corresponding to different tumour constituents and perifocal oedema. In conclusion, the high spatial resolution of MRI enables a detailed analysis of tumour blood flow.

The MRT and CT images of histologically confirmed intracranial ependymomas in 10 patients have been compared. All tumours were demonstrated by CT and MRT. The solid portions of the tumours showed variation in density on CT (hypodense, isodense, hyperdense, or mixed), whereas there was uniform signal intensity on MRT (T1 weighted: hypointense, T2 weighted: hyperintense). Cystic portions of the tumours (6 patients) were shown equally well by both procedures, calcifications were only shown by CT. All ependymomas were related to the ventricles. On unenhanced CT only 3 tumours were clearly delineated, whereas MRT defined all tumours satisfactorily. The significant advantage of MRT is better topographic demonstration of the tumour.

Purpose: To investigate the efficacy of 0.025, 0.05 and 0.1 mmol/kg gadopentetate dimeglumine in MR imaging of patients with intracranial tumors at mid and high field strength., Methods: In 88 patients, an open-label phase III multicenter dose-finding study was performed at 0.5, 1.0, and 1.5 T MR units. Before and after (5, 15, 25 minutes) intravenous administration of gadopentetate dimeglumine, imaging was performed with T1-weighted spin-echo sequences., Results: With 0.1 mmol/kg yielding the highest values, tumor enhancement and numerical tumor/brain contrast showed dose-dependent 5-minute postcontrast values (P less than 0.05). Compared to 5-minute postcontrast values, there was no significant change at 15 and 25 minutes. Although the lowest values of enhancement were found at 0.5 T, differences in enhancement among the field strengths were not statistically significant. The numerical data were confirmed by visual assessment of tumor/brain contrast. Eighty to 90% of cases had diagnostically valuable enhancement at 0.1 mmol/kg, 50% at 0.05 mmol/kg, and 10% at 0.025 mmol/kg (P less than 0.05). There were no adverse events., Conclusion: Our results confirm that 0.1 mmol/kg gadopentetate dimeglumine is more effective at enhancing intracranial tumors than lower doses at mid and high field MR units.

Sensitivity and specificity of plain T2-WI and Gd-DTPA enhanced T1-WI were compared by evaluating MR exams of 30 patients with brain metastases. Large lesions with high signal on T2-WI always enhanced (43/43) when a structure (perifocal edema, tumor tissue, central necrosis) was found. Large lesions nearly always enhanced (53/55) even if no such structure was found. 65% of small unstructured white matter lesions with high signal on T2-WI, which are generally considered vascular, did not enhance. Surprisingly, 35% did enhance. Demonstration of blood brain barrier disturbance in these lesions suggested a metastatic origin. In 3 patients with multiple metastases, Gd-DTPA enhanced T1-WI disclosed more than 140 lesions not seen on T2-WI. All of them were located in or adjacent to grey matter. Our results indicate that enhanced T1-WI should be obtained even if T1-WI are normal or show only small white matter lesions.

The diagnostic value of various doses of Gd-DTPA was compared intra-individually. Thirty-three patients with cerebral tumours were randomly allocated to three groups. Group 1 was given a dose of 0.025, group 2 a dose of 0.05 and group 3 a dose of 0.1 mmol GD-DTPA/kg body weight. Following administration of Gd-DTPA the average tumor/brain contrast in group 1 was -4.5%, in group 2 +8.4% and in group 3 +43.0%. Diagnostically useful tumour delineation was obtained in two out of 11 in group 1, in seven out of 11 in group 2 and in 10 out of 11 in group 3. A further increase in the dose to 0.2 mmol/kg body weight in group 3 resulted in a further increase in tumour/brain contrast of +62.5% and improved tumour delineation in one case. As a result of these findings a dose of 0.1 mmol Gd-DTPA/kg body weight is recommended for the routine investigation of intracranial tumours.

A multisclice gradient echo sequence (FLASH) was compared with a conventional spin-echo (SE) technique with regard to its value for contrast enhanced brain studies. In 50 patients with contrast enhancing intracranial lesions, MR studies (0.5 Tesla MR tomograph) were performed with SE images (SE 400/30; four images/3.4 min) and FLASH scans (FLASH 315/14, 90 degrees; 15 images/1.4 min) before and after Gd-DTPA. Based on visual and quantitative assessment diagnostic results of postcontrast SE- and FLASH images were equivalent with respect to contrast enhancement, lesion/brain-contrast, lesion/edema-contrast, and lesion delineation. Although image quality generally was excellent on postcontrast FLASH images, susceptibility artifacts were more severe on FLASH scans than on SE images. However, with the exception of postoperative patients with artifacts due to metal remains, diagnostic information was not decreased by artifacts on postcontrast FLASH images. In conclusion, because of the clearly higher efficiency of the multisclice FLASH technique, this pulse sequence offers the opportunity to speed up contrast enhanced brain imaging.

Magnetic resonance (MR) imaging was performed on 40 patients with intracranial tumors, before and after intravenous administration of gadolinium-DTPA (Gd-DTPA). Precontrast studies included a comprehensive protocol of spin-echo sequences. Tumors were visualized on precontrast images either directly or indirectly by anatomic distortion caused by the mass. However, differentiation of the tumor from adjacent tissues was possible in only 17 of 40 cases. Delineation of the tumor was best on precontrast, T2-weighted images. After administration of Gd-DTPA (0.1 mmol/kg), increased signal intensity from the tumor was observed in all patients. The localized increase in signal intensity in the tumor considerably improved the tumor delineation in 36 of 40 patients. Whereas most of the meningiomas, neuromas, and adenomas could be delineated prior to administration of contrast material if appropriate pulse sequences were applied, glioblastomas and intracranial metastases required Gd-DTPA administration for diagnostically sufficient tumor display.

One hundred and fifty gadolinium(Gd)-DTPA studies in patients with intracranial tumors were performed. In meningiomas (n = 37) Gd-DTPA is useful to delineate isointense tumors. In acoustic neuromas (n = 16) Gd-DTPA helps to identify intracanalicular tumor tissue. In pituitary adenomas (n = 16) para- or suprasellar tumor extension can be better appreciated after Gd-DTPA injection. In glioblastomas (n = 23) Gd-DTPA provides data on differential diagnosis through the characteristic shape of enhancement. In a variety of tumor types the high contrast between enhancing tumor tissue and adjacent structures facilitates therapy planning. Fast imaging sequences now allow for dynamic Gd-DTPA studies. The time-course of enhancement may increase specificity of magnetic resonance imaging.

The results of the first 71 magnetic resonance studies in 57 children are analysed. Indications, advantages and disadvantages of MR in this age group are described and compared with the results reported in recent literature.

21 patients with clinical and CT diagnoses of intracranial tumor were studied by MRI (NMR) prior to and after administration of intravenous Gadolinium-DTPA. Resultant MRI images were compared with corresponding CT sections with respect to lesion detection, contrast enhancement, tumor delineation and visualization of perifocal edema. All intracranial lesions shown on CT were identified on MRI. Contrast enhancement in MRI images was achieved in 19 out of 21 patients, as it was also with CT. In these cases improved differentiation between tumor, perifocal edema and adjacent brain structures were obtained. In most cases sufficient visualization of perifocal edema in MRI required T2 weighted images (SE 1600/70) in addition to spin echo scans routinely performed prior to and after contrast medium (SE 400/30 or 800/30). No side effects were encountered following administration of Gadolinium-DTPA. The good tolerance and the efficacy justifies the use of Gadolinium-DTPA for contrast enhanced MRI imaging.

A multislice gradient echo sequence (FLASH) was compared with a conventional spin-echo (SE) technique with regard to its value for contrast enhanced MR diagnosis. In 28 patients with cerebral tumours, SE images (SE 400/30; four images/3.4 minutes) and FLASH images (FLASH 315/14; 15 images/1.4 minutes) were obtained before and after gadolinium DTPA. After gadolinium-DTPA results were comparable for both techniques with respect to contrast enhancement, tumor contrast and delineation. Because of the higher efficiency of the FLASH 315/14 technique, this sequence is the method of choice for contrast enhanced cerebral MR imaging.

This study examines the effect of the NMR contrast medium gadolinium-DTPA on image contrast in cerebral tumours. Sixteen patients with space-occupying cerebral lesions were examined on a 0.35 Tesla superconducting scanner, using a T1-weighted spinecho sequence prior to and after the intravenous application of gadolinium-DTPA. In 8 patients T2-weighted spinecho-sequences were obtained before the administration of contrast. The tomograms were evaluated visually and according to quantitative criteria. The use of gadolinium-DTPA helps to evaluate the blood-brain barrier and improves diagnosis by differentiating tumour tissue from edema and from normal brain tissue.

In 36 patients with intracranial tumors, gadolinium (Gd)-DTPA-enhanced SE 400/35, SE 800/35 and IR 1500/400/35 sequences were intraindividually compared. Contrast enhancement usually was shown to better advantage with the IR sequence. Post-contrast SI of tumor tissue was isointense with white matter on IR images in many cases whereas SE sequences displayed enhancing tumor with high contrast versus brain. Post-contrast tumor delineation, therefore, was better with the SE sequences especially in white matter lesions without perifocal edema. The SE 400/35 sequence which allows for contrast-enhanced MRI within a relatively short time is suggested for Gd-DTPA studies of brain tumors.

Peritumoral edema associated with 76 supratentorial meningiomas was studied. The results of radiological investigation (CT, NMR, Angiography) and histological studies are described and correlated to each other. Mechanical factors alone are not sufficient to explain edema in the majority of the cases. It may be assumed that a secretory activity of the tumor itself also plays a role. The mechanism of this is described and discussed.

Time-dependent changes in the contrast enhancement of tumor tissue, tumor necrosis, perifocal edema, and normal brain tissue after IV injection of 0.1 mmol gadolinium-DTPA/kg body weight were studied with spin-echo technique (SE 800/35) in 15 patients with intracranial tumors. Using a region of interest technique, we determined the signal-intensity values of these tissues before and at fixed times up to 68.5 min after administration of the contrast agent. In tumor tissue, the 8.5 min postinjection (p.i.) scan showed a significant increase in signal intensity. The signal intensity of the tumor tissue remained significantly higher than precontrast levels throughout the entire period of observation, decreasing only slightly toward the end of the examination (48.5 and 68.5 min p.i.). Central tumor necrosis exhibited a delayed uptake of the contrast agent, with a maximum signal intensity between 48.5 and 68.5 min p.i. In perifocal edema and normal brain tissue, slight increases in signal intensity after injection of gadolinium-DTPA were measured (statistically significant in the case of edema). This effect, however, was not visually detectable. The present study shows that after one injection, scans with excellent tumor visualization can be obtained between 8.5 and 38.5 min p.i. and with diagnostically valid enhancement at least up to 68.5 min p.i.

In 56 patients with intracranial tumor T2-weighted multi echo (ME) [TR: 1600 ms, TE: 30 to 240 ms (8 echoes)] and T1-weighted Gd-DTPA-enhanced images (TR: 400 ms, TE: 30 ms or 35 ms) were compared with respect to tumor contrast and tumor delineation. In subgroups of 20 and 14 patients, respectively, tumor/brain- and tumor/edema-contrast were assessed on both a subjective and a quantitative basis (contrast-to-noise ratio, CNR). CNR's for tumor/brain-contrast were significantly higher on Gd-DTPA enhanced images than on ME scans. No significant differences between techniques were found for CNR's of tumor/edema-contrast. ME images yielded pathological findings in 54 of the 56 patients but visually assessed tumor delineation was achieved in only 36 cases. Fifteen out of 25 intraaxial tumors and 5 out of 31 extraaxial tumors could not be sufficiently delineated on ME images. In contrast, Gd-DTPA-enhanced images provided differentiation of tumor and surrounding tissues in 55 of 56 studies. In conclusion, ME images have proved highly sensitive in detecting intracranial lesions. However, brain tumors, especially intraaxial tumors could often not be differentiated from adjacent tissues on ME images. After Gd-DTPA, T1-weighted images provided more reliable tumor detection and delineation.)

In order to compare the validity of CT and MRI, we evaluated results of these studies in 40 children and adolescents suffering from supratentorial and infratentorial midline tumors. Plain and enhanced CT scans were compared with MRI for sensitivity, specificity and capacity to delineate the tumor. These parameters were evaluated by three independent investigators on a scale with four grades of accuracy. The results demonstrate greater sensitivity and better delineation of the tumor with MRI, but greater specificity in diagnosis of tumors with CT studies.

Nuclear magnetic resonance tomography was performed on 38 patients with intracranial tumours, before and after the administration of contrast, using a 0.35 T Magnetom. The MR examinations included various plain spin-echo sequences (SE 400/35, 800/35, 1600/35, 1600/70, 1600/105, 1600/120) as well as examinations after the iv-administration of gadolinium-DTPA (SE 800/35). On all occasions, the abnormalities were visible without contrast. Differentiation of tumour and its surroundings was possible in 19 out of 38 cases without contrast. Delineation of expansively growing tumours (eg. meningiomas) was possible in twelve out of 14 cases, but in only seven out of 24 cases with infiltrating tumours (eg. glioblastomas). On the other hand, clear differentiation between tumour and adjacent edema and normal brain, respectively, was possible in 35 out of 38 cases after Gadolinium-DTPA.

The present study provides an introduction to the clinical diagnosis of intracranial lesions by means of magnetic resonance tomography (MRT). The demonstration of different tissue qualities (bone and bone marrow, cerebral cortex and medulla, ventricular system (CSF), blood, tumour and perifocal oedema) in the MR tomogram is explained. The principles of specific MRT contrast media and their clinical application in brain tumours are discussed in detail.

Eight patients with angiographically confirmed arteriovenous malformations (AVMs) were studied by CT and MRI. MRI scans were performed with a 0.35 Tesla wholebody scanner using three spin-echo sequences (SE 400/35, SE 1600/35, SE 1600/70). In CT and MRI, pathological findings were obtained in all cases. In MRI AVMs were displayed as lesions of low signal intensity in the applied sequences. Full extent of the lesions as well as the relationship to the surrounding structures were clearly demonstrated in MRI in all patients. Based on the characteristic sequence dependent signal intensity property of the lesions, the differential diagnosis in the sense of an AVM could be obtained by MRI in all cases. Concerning topographical imaging and/or differential diagnosis, MRI was superior to CT in 4 out of 8 cases. MRI offers advantages in the demonstration of AVMs of the cerebral midline, especially in brain stem angiomas.

In 14 patients with the diagnosis of glioblastoma (n = 7) or intracranial metastases (n = 7), magnetic resonance (MR) imaging was performed using a variety of spin-echo (SE) pulse sequences before and after intravenous injection of 0.1 mmol gadolinium-DTPA (Gd-DTPA) per kilogram of body weight. In 10 patients, tumor tissue could not be adequately differentiated from perifocal edema on unenhanced scans with any of the applied pulse sequences. In four cases of intracranial metastases, poor differentiation between tumor and perifocal edema was possible in T2-weighted (SE 1600/70 and SE 1600/105) unenhanced scans. After administration of Gd-DTPA, tumor tissue showed marked contrast enhancement, and tumor delineation was consistently possible on SE 800/35 images. Tumor tissue could be differentiated from perifocal edema on SE 800/70 scans. Gd-DTPA is likely to increase the potential of MR imaging and refine the evaluation of glioblastomas and intracerebral metastases.

Eleven patients with intracranial tumors were investigated with MR imaging at different dose levels of gadolinium-DTPA to determine a safe and effective dose for imaging intracranial tumors. The patients were divided into two groups. Baseline spin-echo images were obtained with a repetition time of 800 msec and an echo time of 35 msec, and a total of 0.1 mmol of gadolinium-DTPA/kg (six patients) or 0.2 mmol gadolinium-DTPA/kg (five patients) was injected according to a fractionated incremental dose regime (0.025, 0.025, and 0.05 mmol/kg and 0.05, 0.05, and 0.1 mmol/kg, respectively). Postcontrast MR was performed after each injection. In group 1 the best visualization was achieved after the third injection in four cases. In one glioblastoma and in a pituitary adenoma tumor margins were well defined at lower dose levels. In group 2, with five patients, the total dose of 0.2 mmol of gadolinium-DTPA/kg (0.05, 0.05, and 0.1) significantly improved tumor visualization after the third injection in only one patient with multiple metastases. No short-term side effects were encountered. In a range of parameters measured in both serum and whole blood, slight transient elevation of serum iron levels was the only appreciable change. As a result of our investigation we conclude that 0.1 mmol of gadolinium-DTPA/kg is a safe and suitable dose for brain-tumor imaging. In selected cases of 0.2 mmol/kg may increase the diagnostic yield.

52 patients with cerebral tumours were examined by both CT and MR. Contrast media containing iodine were used in CT, whereas in MR a paramagnetic contrast medium (gadolinium-DTPA) was applied by IV injection. A comparison of CT and MR findings showed that with both methods it was often not possible to achieve sufficient visualization and delineation of tumour tissue without employing a contrast medium. After application of the contrast medium, the shape and size contrast enhancement in the tumour tissue in both CT and MR was practically identical. This enables direct visualization of the tumour, superior delineation from the adjacent tissue, and differentiation between oedema and tumour, resulting in effective treatment planning which would otherwise not be possible.

The current paper is a review of our experience of 1200 examinations of the brain, using magnetic resonance tomography (MRT), derived from a mixed neurological and neuro-surgical clinic. MRT has advantages in localisation and tissue characterisation. Localisation is improved by the ability to obtain coronal and sagittal images and by the absence of artifacts due to bone in lesions in the middle and posterior fossa. Some tissues and structures (blood, fat, vessels) produce relatively characteristic signals on MRT, which may be important in clinical diagnosis (eg. chronic subdural haematoma). A significant advantage of MRT is its excellent contrast resolution of soft tissues; this results in better demonstration of normal brain anatomy (eg. corticomedullary contrast), areas of demyelinisation (eg. multiple sclerosis) and certain cerebral tumours (eg. astrocytomas). On the basis of our experience, certain indications are defined, depending on the physical characteristics of the method; these are illustrated by clinical examples.

The early results of the use of the MR specific contrast medium gadolinium-DTPA in 40 patients with intracranial tumours are reported. Optimal pulse sequences, contrast dose and timing are discussed. The relationship between the blood-brain barrier and contrast distribution within tumour tissue is elaborated. The clinical significance of the application of contrast agents in the diagnosis of brain tumours is evaluated.

Patients with a brain-stem tumor were studied with NMR. The full extent of the lesion as well as its relationship with the adjacent structures was clearly demonstrated in all cases. Although NMR is, in many aspects, superior to CT and angiography, these examinations remain useful complementary methods.